Frank Shi

Title: Frank Shi: Innovator in Drug Delivery Technologies

Introduction

Frank Shi is a notable inventor based in Downingtown, PA (US). He has made significant contributions to the field of drug delivery through his innovative patents. With a total of 2 patents, his work focuses on the development of peptides that target the epidermal growth factor receptor (EGFR) on human tumor cells.

Latest Patents

Frank Shi's latest patents include "EGFR binding peptides and uses thereof" and "Dimeric high affinity EGFR constructs and uses thereof." The first patent provides short oligopeptides capable of binding to the EGFR on the surface of human tumor cells. It also outlines methods for using these peptides as targeting moieties in more complex compositions, such as conjugates of cytotoxins and liposomal structures for drug delivery. The second patent presents polypeptides comprising EGFR extracellular domains I-III that can form dimeric EGF-binding proteins. This dimeric construct is particularly useful in applications requiring high-affinity EGF binding and can be employed to select agents capable of binding to native EGFR in the presence of EGF.

Career Highlights

Throughout his career, Frank Shi has worked with prominent companies in the biotechnology sector, including Janssen Biotech, Inc. and Centocor, Inc. His experience in these organizations has contributed to his expertise in drug development and delivery systems.

Collaborations

Frank has collaborated with various professionals in his field, including his coworker Wang Bryan. Their joint efforts have further advanced the research and application of drug delivery technologies.

Conclusion

Frank Shi's innovative work in the development of EGFR-targeting peptides showcases his commitment to improving drug delivery methods. His contributions are significant in the ongoing fight against cancer and highlight the importance of innovation in the medical field.